Intraocular chemotherapy for vitreoretinal lymphoma: A review

Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include in...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & experimental ophthalmology 2020-03, Vol.48 (2), p.240-248
Main Authors: Kvopka, Michael, Lake, Stewart R., Smith, Justine R.
Format: Article
Language:English
Subjects:
Autografts
Central nervous system
Chemotherapy
Clinical trials
drug therapy
eye
Immunosuppressive agents
Lymphoma
Metabolites
Methotrexate
Monoclonal antibodies
Radiation
retina
Rituximab
Stem cell transplantation
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4198-1eedbc21a551556ebe19f106940af6df19a2b131e60a985247ef1cb9c11309463
cites cdi_FETCH-LOGICAL-c4198-1eedbc21a551556ebe19f106940af6df19a2b131e60a985247ef1cb9c11309463
container_end_page 248
container_issue 2
container_start_page 240
container_title Clinical & experimental ophthalmology
container_volume 48
creator Kvopka, Michael
Lake, Stewart R.
Smith, Justine R.
description Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate—an anti‐metabolite—and rituximab—an anti‐human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.
doi_str_mv 10.1111/ceo.13668
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2311921126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2311921126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4198-1eedbc21a551556ebe19f106940af6df19a2b131e60a985247ef1cb9c11309463</originalsourceid><addsrcrecordid>eNp10MFKw0AQBuBFFFurB19AAl70kHZns9lkBQ-lVC0UetHzstlOaErSjZukJW9vaqoHwbnMHD5-hp-QW6Bj6GZi0I4hECI-I0PgnPmSRnB-ugWnfECuqmpLKQ1ZIC7JIAARU07jIXle7GqnrWly7TyzwcLWG3S6bL3UOm-f1Q6twzrb6dzL26Lc2EI_eVPP4T7DwzW5SHVe4c1pj8jHy_x99uYvV6-L2XTpGw4y9gFxnRgGOgwhDAUmCDIFKiSnOhXrFKRmCQSAgmoZh4xHmIJJpAEIqOQiGJGHPrd09rPBqlZFVhnMc71D21SKBQCSAbAjvf9Dt7Zx3ftHFUUghADWqcdeGWerymGqSpcV2rUKqDp2qrpO1Xennb07JTZJgetf-VNiByY9OGQ5tv8nqdl81Ud-AXc4fqU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2377166612</pqid></control><display><type>article</type><title>Intraocular chemotherapy for vitreoretinal lymphoma: A review</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Kvopka, Michael ; Lake, Stewart R. ; Smith, Justine R.</creator><creatorcontrib>Kvopka, Michael ; Lake, Stewart R. ; Smith, Justine R.</creatorcontrib><description>Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate—an anti‐metabolite—and rituximab—an anti‐human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.</description><identifier>ISSN: 1442-6404</identifier><identifier>EISSN: 1442-9071</identifier><identifier>DOI: 10.1111/ceo.13668</identifier><identifier>PMID: 31680408</identifier><language>eng</language><publisher>Melbourne: John Wiley &amp; Sons Australia, Ltd</publisher><subject>Autografts ; Central nervous system ; Chemotherapy ; Clinical trials ; drug therapy ; eye ; Immunosuppressive agents ; Lymphoma ; Metabolites ; Methotrexate ; Monoclonal antibodies ; Radiation ; retina ; Rituximab ; Stem cell transplantation ; Targeted cancer therapy ; Tumors</subject><ispartof>Clinical &amp; experimental ophthalmology, 2020-03, Vol.48 (2), p.240-248</ispartof><rights>2019 Royal Australian and New Zealand College of Ophthalmologists</rights><rights>2019 Royal Australian and New Zealand College of Ophthalmologists.</rights><rights>2020 Royal Australian and New Zealand College of Ophthalmologists</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4198-1eedbc21a551556ebe19f106940af6df19a2b131e60a985247ef1cb9c11309463</citedby><cites>FETCH-LOGICAL-c4198-1eedbc21a551556ebe19f106940af6df19a2b131e60a985247ef1cb9c11309463</cites><orcidid>0000-0002-4756-5493</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31680408$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kvopka, Michael</creatorcontrib><creatorcontrib>Lake, Stewart R.</creatorcontrib><creatorcontrib>Smith, Justine R.</creatorcontrib><title>Intraocular chemotherapy for vitreoretinal lymphoma: A review</title><title>Clinical &amp; experimental ophthalmology</title><addtitle>Clin Exp Ophthalmol</addtitle><description>Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate—an anti‐metabolite—and rituximab—an anti‐human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.</description><subject>Autografts</subject><subject>Central nervous system</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>drug therapy</subject><subject>eye</subject><subject>Immunosuppressive agents</subject><subject>Lymphoma</subject><subject>Metabolites</subject><subject>Methotrexate</subject><subject>Monoclonal antibodies</subject><subject>Radiation</subject><subject>retina</subject><subject>Rituximab</subject><subject>Stem cell transplantation</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>1442-6404</issn><issn>1442-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp10MFKw0AQBuBFFFurB19AAl70kHZns9lkBQ-lVC0UetHzstlOaErSjZukJW9vaqoHwbnMHD5-hp-QW6Bj6GZi0I4hECI-I0PgnPmSRnB-ugWnfECuqmpLKQ1ZIC7JIAARU07jIXle7GqnrWly7TyzwcLWG3S6bL3UOm-f1Q6twzrb6dzL26Lc2EI_eVPP4T7DwzW5SHVe4c1pj8jHy_x99uYvV6-L2XTpGw4y9gFxnRgGOgwhDAUmCDIFKiSnOhXrFKRmCQSAgmoZh4xHmIJJpAEIqOQiGJGHPrd09rPBqlZFVhnMc71D21SKBQCSAbAjvf9Dt7Zx3ftHFUUghADWqcdeGWerymGqSpcV2rUKqDp2qrpO1Xennb07JTZJgetf-VNiByY9OGQ5tv8nqdl81Ud-AXc4fqU</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Kvopka, Michael</creator><creator>Lake, Stewart R.</creator><creator>Smith, Justine R.</creator><general>John Wiley &amp; Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4756-5493</orcidid></search><sort><creationdate>202003</creationdate><title>Intraocular chemotherapy for vitreoretinal lymphoma: A review</title><author>Kvopka, Michael ; Lake, Stewart R. ; Smith, Justine R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4198-1eedbc21a551556ebe19f106940af6df19a2b131e60a985247ef1cb9c11309463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Autografts</topic><topic>Central nervous system</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>drug therapy</topic><topic>eye</topic><topic>Immunosuppressive agents</topic><topic>Lymphoma</topic><topic>Metabolites</topic><topic>Methotrexate</topic><topic>Monoclonal antibodies</topic><topic>Radiation</topic><topic>retina</topic><topic>Rituximab</topic><topic>Stem cell transplantation</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kvopka, Michael</creatorcontrib><creatorcontrib>Lake, Stewart R.</creatorcontrib><creatorcontrib>Smith, Justine R.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical &amp; experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kvopka, Michael</au><au>Lake, Stewart R.</au><au>Smith, Justine R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intraocular chemotherapy for vitreoretinal lymphoma: A review</atitle><jtitle>Clinical &amp; experimental ophthalmology</jtitle><addtitle>Clin Exp Ophthalmol</addtitle><date>2020-03</date><risdate>2020</risdate><volume>48</volume><issue>2</issue><spage>240</spage><epage>248</epage><pages>240-248</pages><issn>1442-6404</issn><eissn>1442-9071</eissn><abstract>Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate—an anti‐metabolite—and rituximab—an anti‐human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.</abstract><cop>Melbourne</cop><pub>John Wiley &amp; Sons Australia, Ltd</pub><pmid>31680408</pmid><doi>10.1111/ceo.13668</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4756-5493</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1442-6404
ispartof Clinical & experimental ophthalmology, 2020-03, Vol.48 (2), p.240-248
issn 1442-6404
1442-9071
language eng
recordid cdi_proquest_miscellaneous_2311921126
source Wiley-Blackwell Read & Publish Collection
subjects Autografts
Central nervous system
Chemotherapy
Clinical trials
drug therapy
eye
Immunosuppressive agents
Lymphoma
Metabolites
Methotrexate
Monoclonal antibodies
Radiation
retina
Rituximab
Stem cell transplantation
Targeted cancer therapy
Tumors
title Intraocular chemotherapy for vitreoretinal lymphoma: A review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T22%3A44%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intraocular%20chemotherapy%20for%20vitreoretinal%20lymphoma:%20A%20review&rft.jtitle=Clinical%20&%20experimental%20ophthalmology&rft.au=Kvopka,%20Michael&rft.date=2020-03&rft.volume=48&rft.issue=2&rft.spage=240&rft.epage=248&rft.pages=240-248&rft.issn=1442-6404&rft.eissn=1442-9071&rft_id=info:doi/10.1111/ceo.13668&rft_dat=%3Cproquest_cross%3E2311921126%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4198-1eedbc21a551556ebe19f106940af6df19a2b131e60a985247ef1cb9c11309463%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2377166612&rft_id=info:pmid/31680408&rfr_iscdi=true